Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

FDA grants EUA for Eli Lilly treatment in conjunction with Remdesivir

Fri 20 November 2020 14:26 | A A A

No recommendation

No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.

(Sharecast News) - The Food and Drug Administration has granted Emergency Use Approval for baricitinib, a treatment for Covid-19 developed jointly by Eli Lilly and Incyte, in combination with Gilead Sciences's remdesivir.

EUA has been granted for use in adult and pediatric patients who require supplemental oxygen, invasive mechanical ventilation or extracorporeal membrane oxygenation.

In the case of Eli Lilly, it marked the second EUA obtained from the same drug regulator for one of its Covid-19 treatments.

On 9 November, the FDA granted EUA for Eli's neutralising antibody treatment for Covid-19 in high-risk non-hospitalised patients.

A clinical trial to determine baricitinib's efficacy and safety as a treatment for COVID-19 was ongoing.

As of 1422 GMT, shares of Eli Lilly were little changed, advancing 0.27% to $143.8, alongside a 0.69% gain for Incyte to $82.25.

    The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.


    More company news from ShareCast